title: Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
abstract: We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil. A 77-yr-old woman was diagnosed as having recurrent hepatocellular carcinoma associated with decompensated liver cirrhosis. We administered enteric-coated tegafur/uracil to this patient. After 1 month of oral administration, there was a decrease in tumor markers. An image analysis showed disappearance of hepatocellular carcinoma. No recurrence of the hepatocellular carcinoma was recognized for 18 months up to the time of the patient's death, which was due to massive bleeding from a hemorrhagic rectal ulcer. At autopsy, the tumor lesion had necrotized. Oral administration of enteric-coated granules containing tegafur/uracil may provide an effective treatment for hepatocellular carcinoma.
authors.affiliation: Third Department of Internal Medicine, Niigata University School of Medicine, Niigata City, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Ichida
authors.forename: Y
authors.initials: Y
authors.lastname: Ishimoto
authors.forename: J
authors.initials: J
authors.lastname: Yokoyama
authors.forename: M
authors.initials: M
authors.lastname: Nomoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ebe
authors.forename: H
authors.initials: H
authors.lastname: Usuda
authors.forename: M
authors.initials: M
authors.lastname: Naito
authors.forename: H
authors.initials: H
authors.lastname: Asakura
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000209:etiology; D012074:Remission Induction; D013608:Tablets, Enteric-Coated; D005641:Tegafur / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014498:Uracil / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D013608:Tablets, Enteric-Coated; D005641:Tegafur; D014498:Uracil